Nordic Nanovector R&D Day unveils updates on several programs
Clinical · LYMRIT 37-01 (relapsed iNHL) - median duration of response of 13.6 months for all responders and 32.0 months for complete responders versus 9.0 months and 20.7 months respectively reported last December at ASH · Archer-1 - 100% ORR (3/3 complete response (CR)) in the first cohort of patients in a phase 1b study of Betalutin® + rituximab in relapsed/refractory follicular lymphoma Preclinical · NOK 6 million in Eurostars funding granted for taking the chimeric alpha-particle emitting anti-CD37 radioimmunoconjugate Alpha37 through the last step towards